TRPM2 and myeloid sarcoma: Genetic deletion of Trpm2 or pharmacological inhibition of TRPM2 with miconazole, an FDA‐approved antifungal drug, alleviates neurological and pathological impairment of EAE pathology by downregulating microglial activation and inhibiting proinflammatory cytokines production in MS mouse models [62, 63].